Výsledky vyhledávání - "Diarrhea/chemically induced"

Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials

Autor: Katarzyna Nabrdalik, Karolina Skonieczna-Żydecka, Krzysztof Irlik, Mirela Hendel, Hanna Kwiendacz, Igor Łoniewski, Kornelia Januszkiewicz, Janusz Gumprecht, Gregory Y. H. Lip

Publikováno v: Nabrdalik, K, Skonieczna-Żydecka, K, Irlik, K, Hendel, M, Kwiendacz, H, Łoniewski, I, Januszkiewicz, K, Gumprecht, J & Lip, G Y H 2022, ' Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus : A systematic review, meta-analysis and meta-regression of randomized controlled trials ', Frontiers in Endocrinology, vol. 13, 975912 . https://doi.org/10.3389/fendo.2022.975912

IntroductionMetformin is the first choice drug in the treatment of type 2 diabetes mellitus but its administration may be linked to gastrointestinal adverse events limiting its use.ObjectivesThe objective of this systematic review and meta-analysis w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8111c19d299579df5560c9fb6516f817

Zobrazit plný text záznamu

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Publikováno v: Bhatt, D L, Szarek, M, Pitt, B, Cannon, C P, Leiter, L A, McGuire, D K, Lewis, J B, Riddle, M C, Inzucchi, S E, Kosiborod, M N, Cherney, D Z I, Dwyer, J P, Scirica, B M, Bailey, C J, Díaz, R, Ray, K K, Udell, J A, Lopes, R D, Lapuerta, P, Steg, P G & SCORED Investigators 2021, ' Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ', The New England Journal of Medicine, vol. 384, no. 2, pp. 129-139 . https://doi.org/10.1056/NEJMoa2030186
NEW ENGLAND JOURNAL OF MEDICINE
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, my

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e9705eeadc025b1e0478507d16cdaa4
https://pure.au.dk/portal/da/publications/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease(6bc50c6b-8a7a-4eea-bd9e-9032680e8b64).html

Zobrazit plný text záznamu

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Publikováno v: K Murthy, R, Loi, S, Okines, A, Paplomata, E, Hamilton, E, A. Hurvitz, S, U. Lin, N, Borges, V, Abramson, V, Anders, C, L. Bedard, P, Oliveira, M, Jakobsen, E, Bachelot, T, S. Shachar, S, Müller, V, Braga, S, P. Duhoux, F, Greil, R, Cameron, D, A. Carey, L, Curigliano, G, Gelmon, K, Hortobagyi, G, Krop, I, Loibl, S, Pegram, M, Slamon, D, Palanca-Wessels, M C, Walker, L, Feng, W & P. Winer, E 2020, ' Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer ', New England Journal of Medicine, vol. 382, no. 7, pp. 597-609 . https://doi.org/10.1056/NEJMoa1914609
Murthy, R K, Loi, S, Okines, A, Paplomata, E, Hamilton, E, Hurvitz, S A, Lin, N U, Borges, V, Abramson, V, Anders, C, Bedard, P L, Oliveira, M, Jakobsen, E, Bachelot, T, Shachar, S S, Muller, V, Braga, S, Duhoux, F P, Greil, R, Cameron, D, Carey, L A, Curigliano, G, Gelmon, K, Hortobagyi, G, Krop, I, Loibl, S, Pegram, M, Slamon, D, Palanca-Wessels, M C, Walker, L, Feng, W & Winer, E P 2020, ' Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer ', New England Journal of Medicine, vol. 382, no. 7, pp. 597-609 . https://doi.org/10.1056/NEJMoa1914609
The New England journal of medicine, Vol. 382, no. 7, p. 597-609 (2020)

BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigationa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5309a1bc026281d5d475def4ba6ca36
https://www.pure.ed.ac.uk/ws/files/125147047/NEJMoa1914609.pdf

Zobrazit plný text záznamu

S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma

Autor: Per Pfeiffer, K R Schønnemann, Stine Braendegaard Winther, Mathilde Weisz Ejlsmark, Merete Krogh, Jon Kroll Bjerregaard, Helle Anita Jensen

Publikováno v: Winther, S B, Bjerregaard, J K, Schonnemann, K R, Ejlsmark, M W, Krogh, M, Jensen, H A & Pfeiffer, P 2018, ' S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma ', Cancer Chemotherapy and Pharmacology, vol. 81, no. 3, pp. 573–578 . https://doi.org/10.1007/s00280-018-3528-5

PURPOSE: Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades. Randomized, primarily Japanese, studies have shown promising efficacy when combined with S-1 (GemS-1); however, no data are published i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9970c5b1ee7299ad820c5800d2fedc51
https://doi.org/10.1007/s00280-018-3528-5

Zobrazit plný text záznamu

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Publikováno v: Flaherty, KR, Cottin, V, Devaraj, A, Walsh, SLF, Inoue, Y, Richeldi, L, Kolb, M, Tetzlaff, K, Stowasser, S, Coeck, C, Clerisme-Beaty, E, Rosenstock, B & Investigators, INBUILD T 2019, ' Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. ', The New England Journal of Medicine . https://doi.org/10.1056/nejmoa1908681
The New England journal of medicine, 381 (18
The New England journal of medicine, Vol. 381, no. 18, p. 1718-1727 (2019)

Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression of lung fibrosis. Although the efficacy of nintedanib has been shown in idiopathic pulmonary fibrosis, its

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64927cb9d80ef77446ccc9456d960307
https://research.manchester.ac.uk/en/publications/1182fb9c-aa79-40fa-9349-8af883fd6706

Zobrazit plný text záznamu

Adverse events in people taking macrolide antibiotics versus placebo for any indication

Autor: Jeffrey K Aronson, Malene Plejdrup Hansen, Anna Mae Scott, Elaine Beller, Justin Clark, Chris Del Mar, Paul Glasziou, Sarah Thorning, Amanda McCullough, Tammy Hoffmann

Publikováno v: The Cochrane Library
Hansen, M P, Scott, A M, McCullough, A, Thorning, S, Aronson, J K, Beller, E M, Glasziou, P P, Hoffmann, T C, Clark, J & Mar, C B D 2019, ' Adverse events in people taking macrolide antibiotics versus placebo for any indication ', Cochrane Database of Systematic Reviews, vol. 2019, no. 1, CD011825 . https://doi.org/10.1002/14651858.CD011825.pub2

BACKGROUND: Macrolide antibiotics (macrolides) are among the most commonly prescribed antibiotics worldwide and are used for a wide range of infections. However, macrolides also expose people to the risk of adverse events. The current understanding o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e77a101af5840b70d073cf8754163a9
http://ora.ox.ac.uk/objects/uuid:

Zobrazit plný text záznamu

Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger

Autor: Joachim Roesler, Michael Hofer, X Wei, Inmaculada Calvo Penades, Helen J. Lachmann, Paul A. Brogan, Laurence Goffin, Jasmin B Kuemmerle-Deschner, Ronald M. Laxer, Bernard Lauwerys, Isabelle Koné-Paut, Gerd Horneff, Tilmann Kallinich, Yosef Uziel, Belén Sevilla‐Perez

Publikováno v: ARTHRITIS & RHEUMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Arthritis & rheumatology, vol. 71, no. 11, pp. 1955-1963
Arthritis & rheumatology (Hoboken, N.J.), Vol. 71, no.11, p. 1955-1963 (2019)
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & rheumatology, 71 (11

Objective: To assess long-term efficacy and safety of canakinumab and the response to vaccination in children ages ≤5 years with cryopyrin-associated periodic syndrome (CAPS). Methods: CAPS patients (ages ≤5 years) received 2 mg/kg canakinumab su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8d94e3ab22bdb788a19faa97c1162f2
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11116

Zobrazit plný text záznamu

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Autor: Distler, O, Highland, Kb, Gahlemann, M, Azuma, A, Fischer, A, Mayes, Md, Raghu, G, Sauter, W, Girard, M, Alves, M, Clerisme-Beaty, E, Stowasser, S, Tetzlaff, K, Kuwana, M, Maher, Tm, Bergna, M, Casado, G, Mannucci Walter, P, Proudman, S, Stevens, W, Thakkar, V, Troy, L, Loeffler-Ragg, J, Olschewski, H, Bondue, B, Houssiau, F, Smith, V, Wuyts, W, Johnson, S, Keystone, E, Khalidi, N, Levesque, M, Maturana Rozas, R, Silva Orellana, A, Huang, C, Li, J, Jiang, Z, Liu, Y, Xiao, W, Xu, J, Zeng, X, Zheng, Y, Zou, H, Becvar, R, Madsen, H, Søndergaard, K, Kilpeläinen, M, Myllärniemi, M, Agard, C, Allanore, Y, Bourdin, A, Cottin, V, Crestani, B, Diot, E, Dominique, S, Hachulla, E, Jouneau, S, Leroy, S, Nunes, H, Prevot, G, Wallaert, B, Wemeau, L, Aringer, M, Bewig, B, Blaas, S, Distler, J, Ehrchen, J, Ewert, R, Gläser, S, Henes, J, Hunzelmann, N, König, R, Kötter, I, Kreuter, M, Prasse, A, Schulze-Koops, H, Sfikakis, P, Vlachoyiannopoulos, P, Losonczy, G, Behera, D, Gayathri Devi HJ, Kadel, J, Kawedia, M, Kumar, D, Kumar, U, Lokhande, R, Malpani, A, Mohan, M, Nalawade, A, Parakh, U, Swarnakar, R, Shobha, V, Thangakunam, B, Udwadia, Z, Henry, M, O'Reilly, K, Balbir-Gurman, A, Kramer, M, Litinsky, I, Rosner, I, Cutolo, M, Gabrielli, A, Iaccarino, L, Pesci, A, Riccieri, V, Vettori, S, Funakubo, Y, Inoue, Y, Kawakami, A, Kawaguchi, Y, Kawamura, T, Kondoh, Y, Nanki, T, Nishioka, Y, Nozawa, K, Oguragawa, T, Okamoto, M, Sano, H, Sasai, R, Sasaki, N, Suda, T, Takahashi, H, Takeuchi, T, Tanaka, S, Yamasaki, Y, Ch'Ng, Ss, Cheah, C, Kan, S, Raja Mohamed RB, Selman, M, de Vries-Bouwstra JK, van den Toorn, L, Vonken, M, Voskuyl, Ae, Hoffmann-Vold, Am, Seip, M, Dankiewicz-Fares, I, Olesiejuk, R, Pulka, G, Szepietowski, J, Alves, J, Bernardes, M, Cordeiro, A, Costa, J, Neves, S, Salvador, Mj, Alegre Sancho, J, Carreira Delgado, P, Castellví Barranco, I, Cifrián Martínez, J, Guillén Del Castillo, A, Ovalles, Jg, López-Longo, Fj, Rivera Gallego, A, Freire Dapena MC, Román Ivorra JA, Ekwall, Ah, Maurer, B, Mihai, Cm, Müller, R, Mahakkanukrauh, A, Nantiruj, K, Siripaitoon, B, Denton, Cp, Herrick, A, Madhok, R, West, A, Bascom, R, Criner, G, Csuka, Me, Dematte D'Amico, J, Ettinger, N, Gerbino, A, Gerke, A, Glassberg, M, Glazer, C, Golden, J, Gripaldo, R, Gupta, N, Hamblin, M, Highland, K, Ho, L, Huggins, Jt, Hummers, L, Jones, L, Kahaleh, M, Khanna, D, Kim, H, Lancaster, Lh, Luckhardt, T, Mayes, M, Mendoza Ballesteros, F, Mooney, J, Mohabir, P, Morrissey, B, Moua, T, Padilla, M, Patel, N, Perez, R, Roman, J, Rossman, M, Russell, T, Saketkoo, L, Shah, A, Shlobin, O, Scholand, Mb, Simmssetts, R, Spiera, R, Steen, V, Veeraraghavan, S, Weigt, S.

Publikováno v: The New England journal of medicine, 380 (26

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in prec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e118eeba1a57a3cf6124b2033e5e816
http://hdl.handle.net/11591/408594

Zobrazit plný text záznamu

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome

Autor: Allison R. Schulman, Andrew S. Allegretti, Alison Goldin, Manol Jovani, Mads Israelsen, Lise Lotte Gluud, Rachel W. Winter, Aleksander Krag

Publikováno v: The Cochrane Library
Allegretti, A S, Israelsen, M, Krag, A, Jovani, M, Goldin, A H, Schulman, A R, Winter, R W & Gluud, L L 2017, ' Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome ', Cochrane Database of Systematic Reviews, vol. 6, no. 6, CD005162 . https://doi.org/10.1002/14651858.CD005162.pub4

Background Hepatorenal syndrome is a potentially reversible renal failure associated with severe liver disease. The disease is relatively common among people with decompensated cirrhosis. Terlipressin is a drug that increases the blood flow to the ki

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eda84792d2b1feceff11da7f7c001de9
https://doi.org/10.1002/14651858.cd005162.pub4

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání